2024-01-01 12:54:59
Wanda Nara revealed for the first time what type of leukemia she suffers from
The year 2023 marked a turning point in Wanda Nara’s life. During these twelve months, she experienced everything from professional triumphs to facing a personal health challenge. Her life, normally public, became more private following learning of her leukemia diagnosis. The analyses, which initially seemed routine, revealed a more complex situation. As of July 2023, she began treatment that has shown positive results.
This change in his life and approach to privacy contrasted sharply with his usual public image. Wanda chose to keep details of her health confidential until she was ready to share them. The leukemia diagnosis marked a critical moment for her, in which her main goal became overcoming the disease and ensuring that her children handled the situation in the best way possible.
First he only called it a “disease,” then he admitted that it was “leukemia,” as several media outlets had revealed, but until now he had avoided specifying what type of cancer he was dealing with.
Finally, in the last few hours he published his diagnosis for the first time through the social network Instagram, where he has almost 17 million followers. According to the photo of the document that she revealed, Wanda was diagnosed with chronic myeloid leukemia by FUNDALEU specialists.
Wanda Nara’s medical report indicating that she has chronic myeloid leukemia (Instagram)
“We inform you that the patient Wanda Solange Nara has been under follow-up at FUNDALEU since July 2023 for Chronic Myeloid Leukemia with a satisfactory response to the treatment administered. “She carries out periodic studies in Argentina and Turkey to control her illness,” reads the document signed by Dr. Miguel A. Pavlovsky of the Medical Directorate of FUNDALEU.
As a general concept, leukemia is a type of cancer that originates in the bone marrow and consists of an uncontrolled production of abnormal or ‘malignant’ cells. Although it is not a solid tumor, as in other types of cancer, it is considered an oncohematological disease.
“Bone marrow is a tissue found inside the bones and is the place where blood cells (red blood cells, white blood cells and platelets) are formed. There are acute leukemias (that progress quickly, in a few weeks) and chronic leukemias (that progress more slowly, in several months); and within them there are different types,” Dr. Francisca Rojas (MN 90648), head of the Hematology Division of the Hospital de Clínicas “Gral. José de San Martín”, the institution dependent on the Faculty of Medicine of the University of Buenos Aires (UBA).
Although leukemias are not preventable, as is the case with around a third of cancer cases, they share many aspects, such as the importance of early detection and access to the most appropriate treatment for each type and stage of disease.
“If it is chronic myeloid leukemia or chronic lymphatic leukemia, patients have very good responses and recover, so they can have a life,” Dr. Moiraghi added to Infobae.
Chronic myeloid leukemia (CML) affects myeloid cells and usually grows slowly at first. It mainly affects adults.
Dr. Alicia Enrico, hematologist at the Italian Hospital of La Plata, explained to Infobae the most common types of leukemia in a recent note. “We can say that there are acute and chronic leukemias. They differ in the way they are presented. The acute ones are too expressive to be called anything, while the chronic ones are often findings in a routine study. If we focus on the chronic ones, we can affirm that there are those that affect individuals over 70 years of age, which is chronic lymphatic leukemia. The one that affects adults but not so old is called chronic myeloid,” said the expert.
And he added: “Chronic myeloid leukemia is a disease that has had many scientific advances in recent years, especially since 2001. It is a disease with a very specific lesion in which new drugs are used for its treatment. “They are called drugs with molecular targets, which allow the disease to change its prognosis and allow patients to have a life expectancy almost similar to that of healthy individuals.”
“The treatments available for the disease are called tyrosine kinase inhibitors. There are 1st, 2nd and 3rd generation. A tyrosine kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more proteins (as the name suggests, kinases) by preventing diseased cells from growing and thereby restoring blood counts to normal. “Enrico specified.
For the early detection of leukemia, the important thing is to do blood counts (Getty)
In this sense, consulted by Infobae, hematologist Beatriz Moiraghi, from the Ramos Mejía Hospital in the City of Buenos Aires, explained that “within acute leukemias, there is acute lymphoblastic leukemia and acute myeloblastic leukemia.” “Within the chronic leukemias, there is chronic lymphocytic (CLL) and chronic myeloid,” she added.
Regarding the symptoms and how to arrive at the diagnosis, the specialist explained that “for the early detection of leukemia, the important thing is to do periodic hemograms (blood tests). One of the symptoms of any type of leukemia, and especially in chronic ones, is that the patient has weight loss, lack of appetite, heaviness in the belly area, pain in the abdomen due to inflammation of the spleen and/or liver or bone pain due to the increase in white blood cells.”
The multicenter AST (Argentina Stop Trial) study, carried out at the Alexander Fleming Institute in collaboration with Fundaleu
“If it is chronic myeloid leukemia or chronic lymphatic leukemia, patients have very good responses and recover, so they can have a life,” Dr. Moiraghi added to Infobae.
As Infobae recently published, researchers from CONICET in Argentina published two studies that reveal significant advances in the treatment of chronic myeloid leukemia (CML). The studies, published in Frontiers in Immunology y Journal of Hematology and Oncology, They would allow an increase in the number of patients who discontinue treatment with tyrosine kinase inhibitors (TKIs), improving their quality of life and reducing medical costs. This news is relevant to the approximately 450 [15% de los 3000 diagnósticos anuales] cases of CML diagnosed every year in the country.
The research, led by Dr. Michele Bianchini from the Cancer Research Center – Cancer Foundation (FUCA) and which began in 2019, aims to establish safe criteria for discontinuation of treatment in Argentina and find new biomarkers to predict with high precision (close 90%) who can maintain long-term remission. The multicenter AST (Argentina Stop Trial) study, carried out at the Alexander Fleming Institute in collaboration with FUNDALEU and public hospitals, showed that high levels of two immune system proteins, interleukin 6 (IL-6) and monocyte chemoattractant protein ( MCP-1), are associated with successful treatment discontinuation.
1704123325
#Chronic #myeloid #leukemia #prognosis #type #cancer #Wanda #Nara #suffers
